Experimental immune cell therapy targets Hard-to-Treat cancers
NCT ID NCT05430360
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then infused back after a short course of chemotherapy. The study aimed to check safety and whether the treatment could shrink tumors, but it was stopped early after enrolling only 2 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GT201 (autologous tumor-infiltrating lymphocyte injection)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have come back or spread.
What could go wrong
This is a very early, small trial (only 2 participants enrolled) that was terminated, so results are limited. The therapy involves strong chemotherapy and may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Zhejiang University
Hangzhou, Zhejiang, China